Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Strong-Buy” at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Friday.

Separately, Cantor Fitzgerald reissued a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $33.43 on Friday. The firm’s fifty day simple moving average is $31.88 and its 200-day simple moving average is $34.83. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of 31.24 and a beta of 0.74. Supernus Pharmaceuticals has a 12 month low of $25.53 and a 12 month high of $40.28.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Supernus Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock worth $222,411,000 after purchasing an additional 22,852 shares during the period. Armistice Capital LLC grew its stake in shares of Supernus Pharmaceuticals by 7.4% during the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company’s stock worth $170,169,000 after purchasing an additional 360,000 shares during the period. Geode Capital Management LLC boosted its position in shares of Supernus Pharmaceuticals by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock worth $54,633,000 after buying an additional 28,517 shares in the last quarter. GW&K Investment Management LLC boosted its position in shares of Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company’s stock worth $45,275,000 after buying an additional 176,091 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Supernus Pharmaceuticals by 9.2% in the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after buying an additional 95,777 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.